
Opinion|Videos|August 20, 2024
Optimizing MOAs of JAK Inhibitors in a 36-Year-Old Male With a History of Atopic Dermatitis
Author(s)Jayme M. Heim, MSN, FNP-BC
Jayme Heim, MSN, FNP-BC, explores strategies for optimizing the mechanisms of action of topical JAK inhibitors in treating a 36-year-old male patient with a history of atopic dermatitis, highlighting the potential benefits and considerations of this therapeutic approach.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
3
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
4
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
5












